Acute otitis media in infants younger than three months not vaccinated against Streptococcus pneumoniae

n/

Acute otitis media in infants younger than three months not vaccinated against Streptococcus pneumoniae

n/

Serotype distribution of pneumococci isolated from pediatric patients with acute otitis media and invasive infections, and potential coverage of pneumococcal conjugated vaccines

Fil: Reijtman, Vanesa R. Servicio de Microbiología, Hospital de Pediatría, Ciudad Autónoma de Buenos Aires; Argentina.Fil: Fossati, Sofía. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas; Argentina.Fil: Hernández, Claudia. Servicio de Microbiología, Hospital de Pediatría, Ciudad Autónoma de Buenos Aires; Argentina.Fil: Sommerfleck, Patricia. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas; Argentina.Fil: Bernáldez, Patricia. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas; Argentina.Fil: Litterio, Mirta. Servicio de Microbiología, Hospital de Pediatría, Ciudad Autónoma de Buenos Aires; Argentina.Fil: Berberian, Griselda. Servicio de Control Epidemiológico e Infectología, Hospital de Pediatría “Prof. Dr. Juan P. Garrahan”; Argentina.Fil: Regueira, Mabel. Servicio de Otorrinolaringología, Hospital de Pediatría, Ciudad Autónoma de Buenos Aires; Argentina.Fil: Lopardo, Horacio. Servicio de Microbiología, Hospital de Pediatría, Ciudad Autónoma de Buenos Aires; Argentina.A 16-month prospective, descriptive study was conducted on pneumococcal serotype distribution isolated from children with acute otitis media (AOM) and invasive infections (INV). Eighty-nine children with pneumococcal INV and 324 with a first episode of AOM were included. Bacterial pathogens (N = 326) were isolated from the middle-ear fluid of 250 patients. A total of 30 pneumococcal serotypes were identified. Prevalent serotypes were 14, 19A, 9V, 3, 19F, 6A, 23F, and 18C in AOM and 14, 1, 19A, 5, 12F, 6B, and 18C in INV. Potential coverage with PCV10 vaccine would be 46.5 % and 60.7 % for pneumococci involved in AOM and INV, respectively; it would be 71.7 % and 73 % with PCV13. PCV10, conjugated with a Haemophilus protein, would have an immunologic coverage of 39.9 % for AOM vs. 18.5 % with PCV13. However, differences in the prevention of INV were crucial for the decision to include the 13-valent vaccine in the national calendar for children less than two years old in Argentina

Serotype distribution of pneumococci isolated from pediatric patients with acute otitis media and invasive infections, and potential coverage of pneumococcal conjugated vaccines

Fil: Reijtman, Vanesa R. Servicio de Microbiología, Hospital de Pediatría, Ciudad Autónoma de Buenos Aires; Argentina.Fil: Fossati, Sofía. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas; Argentina.Fil: Hernández, Claudia. Servicio de Microbiología, Hospital de Pediatría, Ciudad Autónoma de Buenos Aires; Argentina.Fil: Sommerfleck, Patricia. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas; Argentina.Fil: Bernáldez, Patricia. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas; Argentina.Fil: Litterio, Mirta. Servicio de Microbiología, Hospital de Pediatría, Ciudad Autónoma de Buenos Aires; Argentina.Fil: Berberian, Griselda. Servicio de Control Epidemiológico e Infectología, Hospital de Pediatría “Prof. Dr. Juan P. Garrahan”; Argentina.Fil: Regueira, Mabel. Servicio de Otorrinolaringología, Hospital de Pediatría, Ciudad Autónoma de Buenos Aires; Argentina.Fil: Lopardo, Horacio. Servicio de Microbiología, Hospital de Pediatría, Ciudad Autónoma de Buenos Aires; Argentina.A 16-month prospective, descriptive study was conducted on pneumococcal serotype distribution isolated from children with acute otitis media (AOM) and invasive infections (INV). Eighty-nine children with pneumococcal INV and 324 with a first episode of AOM were included. Bacterial pathogens (N = 326) were isolated from the middle-ear fluid of 250 patients. A total of 30 pneumococcal serotypes were identified. Prevalent serotypes were 14, 19A, 9V, 3, 19F, 6A, 23F, and 18C in AOM and 14, 1, 19A, 5, 12F, 6B, and 18C in INV. Potential coverage with PCV10 vaccine would be 46.5 % and 60.7 % for pneumococci involved in AOM and INV, respectively; it would be 71.7 % and 73 % with PCV13. PCV10, conjugated with a Haemophilus protein, would have an immunologic coverage of 39.9 % for AOM vs. 18.5 % with PCV13. However, differences in the prevention of INV were crucial for the decision to include the 13-valent vaccine in the national calendar for children less than two years old in Argentina